| [1] |
CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367. |
| [2] |
YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431. |
| [3] |
DULAI PS, SINGH S, PATEL J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis[J]. Hepatology, 2017, 65(5): 1557-1565. DOI: 10.1002/hep.29085. |
| [4] |
BROUHA SS, NGUYEN P, BETTENCOURT R, et al. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study[J]. Eur Radiol, 2018, 28(4): 1345-1355. DOI: 10.1007/s00330-017-5075-6. |
| [5] |
MANTOVANI A, ZAZA G, BYRNE CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis[J]. Metabolism, 2018, 79: 64-76. DOI: 10.1016/j.metabol.2017.11.003. |
| [6] |
TILG H, MOSCHEN AR, RODEN M. NAFLD and diabetes mellitus[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(1): 32-42. DOI: 10.1038/nrgastro.2016.147. |
| [7] |
HAN CY. Update on FXR biology: Promising therapeutic target?[J]. Int J Mol Sci, 2018, 19(7): 2069. DOI: 10.3390/ijms19072069. |
| [8] |
PROPERZI C, O'SULLIVAN TA, SHERRIFF JL, et al. Ad libitum mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial[J]. Hepatology, 2018, 68(5): 1741-1754. DOI: 10.1002/hep.30076. |
| [9] |
VILAR-GOMEZ E, VUPPALANCHI R, DESAI AP, et al. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis[J]. Aliment Pharmacol Ther, 2019, 50(3): 317-328. DOI: 10.1111/apt.15331. |
| [10] |
KHAN RS, BRIL F, CUSI K, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease[J]. Hepatology, 2019, 70(2): 711-724. DOI: 10.1002/hep.30429. |
| [11] |
ARMSTRONG MJ, GAUNT P, AITHAL GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet, 2016, 387(10019): 679-690. DOI: 10.1016/S0140-6736(15)00803-X. |
| [12] |
KHNEIZER G, RIZVI S, GAWRIEH S. Non-alcoholic fatty liver disease and diabetes mellitus[J]. Adv Exp Med Biol, 2021, 1307: 417-440. DOI: 10.1007/5584_2020_532. |
| [13] |
REHM J, MATHERS C, POPOVA S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders[J]. Lancet, 2009, 373(9682): 2223-2233. DOI: 10.1016/S0140-6736(09)60746-7. |
| [14] |
REHM J, SAMOKHVALOV AV, SHIELD KD. Global burden of alcoholic liver diseases[J]. J Hepatol, 2013, 59(1): 160-168. DOI: 10.1016/j.jhep.2013.03.007. |
| [15] |
FORD ES, GILES WH, DIETZ WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey[J]. JAMA, 2002, 287(3): 356-359. DOI: 10.1001/jama.287.3.356. |
| [16] |
SINGH A, AMIN H, GARG R, et al. Increased prevalence of obesity and metabolic syndrome in patients with alcoholic fatty liver disease[J]. Dig Dis Sci, 2020, 65(11): 3341-3349. DOI: 10.1007/s10620-020-06056-1. |
| [17] |
GARCIA-COMPEAN D, JAQUEZ-QUINTANA JO, GONZALEZ-GONZALEZ JA, et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management[J]. World J Gastroenterol, 2009, 15(3): 280-288. DOI: 10.3748/wjg.15.280. |
| [18] |
HART CL, MORRISON DS, BATTY GD, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies[J]. BMJ, 2010, 340: c1240. DOI: 10.1136/bmj.c1240. |
| [19] |
ÅBERG F, HELENIUS-HIETALA J, PUUKKA P, et al. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population[J]. Hepatology, 2018, 67(6): 2141-2149. DOI: 10.1002/hep.29631. |
| [20] |
SEITZ HK, BATALLER R, CORTEZ-PINTO H, et al. Alcoholic liver disease[J]. Nat Rev Dis Primers, 2018, 4(1): 16. DOI: 10.1038/s41572-018-0014-7. |
| [21] |
LECLERCQ S, STÄRKEL P, DELZENNE NM, et al. The gut microbiota: A new target in the management of alcohol dependence?[J]. Alcohol, 2019, 74: 105-111. DOI: 10.1016/j.alcohol.2018.03.005. |
| [22] |
POLYZOS SA, KOUNTOURAS J, MANTZOROS CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics[J]. Metabolism, 2019, 92: 82-97. DOI: 10.1016/j.metabol.2018.11.014. |
| [23] |
CONASON A, TEIXEIRA J, HSU CH, et al. Substance use following bariatric weight loss surgery[J]. JAMA Surg, 2013, 148(2): 145-150. hppts: //doi. org/10.1001/2013. jamasurg. 265. DOI: 10.1001/2013.jamasurg.265 |
| [24] |
|
| [25] |
|
| [26] |
LEE WG, WELLS CI, MCCALL JL, et al. Prevalence of diabetes in liver cirrhosis: A systematic review and meta-analysis[J]. Diabetes Metab Res Rev, 2019, 35(6): e3157. DOI: 10.1002/dmrr.3157. |
| [27] |
SPRADLING PR, SIMONS B, NARAYANAN M, et al. Incidence of diabetes mellitus in a population-based cohort of persons with chronic hepatitis B virus infection[J]. J Viral Hepat, 2013, 20(7): 510-513. DOI: 10.1111/jvh.12071. |
| [28] |
CAI C, ZENG J, WU H, et al. Association between hepatitis B virus infection and diabetes mellitus: A meta-analysis[J]. Exp Ther Med, 2015, 10(2): 693-698. DOI: 10.3892/etm.2015.2537. |
| [29] |
DAI CY, YEH ML, HUANG CF, et al. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles[J]. J Gastroenterol Hepatol, 2015, 30(5): 879-884. DOI: 10.1111/jgh.12313. |
| [30] |
HSIANG JC, GANE EJ, BAI WW, et al. Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients[J]. J Gastroenterol Hepatol, 2015, 30(3): 591-599. DOI: 10.1111/jgh.12790. |
| [31] |
ELKRIEF L, CHOUINARD P, BENDERSKY N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C[J]. Hepatology, 2014, 60(3): 823-831. DOI: 10.1002/hep.27228. |
| [32] |
RODRÍGUEZ-ESCAJA C, Á NAVASCUÉS C, GONZÁLEZ-DIÉGUEZ L, et al. Diabetes is not associated with an increased risk of hepatocellular carcinoma in patients with alcoholic or hepatitis C virus cirrhosis[J]. Rev Esp Enferm Dig, 2021, 113(7): 505-511. DOI: 10.17235/reed.2020.6953/2020. |
| [33] |
YOUNOSSI Z, PARK H, HENRY L, et al. Extrahepatic manifestations of hepatitis C: A Meta-analysis of prevalence, quality of life, and economic burden[J]. Gastroenterology, 2016, 150(7): 1599-1608. DOI: 10.1053/j.gastro.2016.02.039. |
| [34] |
ELKRIEF L, RAUTOU PE, SARIN S, et al. Diabetes mellitus in patients with cirrhosis: clinical implications and management[J]. Liver Int, 2016, 36(7): 936-948. DOI: 10.1111/liv.13115. |
| [35] |
SCHATTENBERG JM, SCHUCHMANN M. Diabetes and apoptosis: liver[J]. Apoptosis, 2009, 14(12): 1459-1471. DOI: 10.1007/s10495-009-0366-2. |
| [36] |
WANG CC, CHENG PN, KAO JH. Systematic review: chronic viral hepatitis and metabolic derangement[J]. Aliment Pharmacol Ther, 2020, 51(2): 216-230. DOI: 10.1111/apt.15575. |
| [37] |
KOIKE K, TSUTSUMI T. The oncogenic role of hepatitis C virus[J]. Recent Results Cancer Res, 2021, 217: 91-105. DOI: 10.1007/978-3-030-57362-1_5. |
| [38] |
CACOUB P, DESBOIS AC, COMARMOND C, et al. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis[J]. Gut, 2018, 67(11): 2025-2034. DOI: 10.1136/gutjnl-2018-316234. |
| [39] |
CIANCIO A, BOSIO R, BO S, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents[J]. J Med Virol, 2018, 90(2): 320-327. DOI: 10.1002/jmv.24954. |
| [40] |
SETO WK, LAU EH, WU JT, et al. Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study[J]. Aliment Pharmacol Ther, 2017, 45(4): 501-509. hppts: //doi. org/10.1111/apt. 13895. DOI: 10.1111/apt.13895 |
| [41] |
LOAEZA-DEL CASTILLO AM, GAYTÁN-SANTILLÁN A, LÓPEZ-TELLO A, et al. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis[J]. Ann Hepatol, 2019, 18(6): 879-882. DOI: 10.1016/j.aohep.2019.07.006. |
| [42] |
HÍNDI M, LEVY C, COUTO CA, et al. Primary biliary cirrhosis is more severe in overweight patients[J]. J Clin Gastroenterol, 2013, 47(3): e28-e32. DOI: 10.1097/MCG.0b013e318261e659. |
| [43] |
LIU X, XU H, ZHAN M, et al. The potential effects of diabetes mellitus on liver fibrosis in patients with primary biliary cholangitis[J]. Med Sci Monit, 2019, 25: 6174-6180. DOI: 10.12659/MSM.916107. |
| [44] |
PANZITT K, JUNGWIRTH E, KRONES E, et al. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis[J]. J Hepatol, 2020, 72(6): 1122-1131. DOI: 10.1016/j.jhep.2020.01.014. |
| [45] |
KAUR A, PATANKAR JV, de HAAN W, et al. Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1[J]. Diabetes, 2015, 64(4): 1168-1179. DOI: 10.2337/db14-0716. |
| [46] |
ZHAO L, XUAN Z, SONG W, et al. A novel role for farnesoid X receptor in the bile acid-mediated intestinal glucose homeostasis[J]. J Cell Mol Med, 2020, 24(21): 12848-12861. DOI: 10.1111/jcmm.15881. |
| [47] |
DEUTSCHMANN K, REICH M, KLINDT C, et al. Bile acid receptors in the biliary tree: TGR5 in physiology and disease[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1319-1325. DOI: 10.1016/j.bbadis.2017.08.021. |
| [48] |
REICH M, KLINDT C, DEUTSCHMANN K, et al. Role of the G protein-coupled bile acid receptor TGR5 in liver damage[J]. Dig Dis, 2017, 35(3): 235-240. DOI: 10.1159/000450917. |
| [49] |
FLOREANI A, CAZZAGON N, FRANCESCHET I, et al. Metabolic syndrome associated with primary biliary cirrhosis[J]. J Clin Gastroenterol, 2015, 49(1): 57-60. DOI: 10.1097/MCG.0000000000000029. |
| [50] |
KJÆRGAARD K, FRISCH K, SØRENSEN M, et al. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis[J]. J Hepatol, 2021, 74(1): 58-65. DOI: 10.1016/j.jhep.2020.07.028. |
| [51] |
GAO Y, LI L, LI B, et al. Response rate and impact on lipid profiles of obeticholic acid treatment for patients with primary biliary cholangitis: A Meta-analysis[J]. Can J Gastroenterol Hepatol, 2021, 2021: 8829510. DOI: 10.1155/2021/8829510. |
DownLoad: